{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:40:33Z","timestamp":1784547633475,"version":"3.55.0"},"reference-count":69,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T00:00:00Z","timestamp":1638835200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pain Res."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Neonatal hypoxia-ischemia encephalopathy (HIE) is the leading cause of neonatal death and poor neurodevelopmental outcomes worldwide. Therapeutic hypothermia (TH), while beneficial, still leaves many HIE treated infants with lifelong disabilities. Furthermore, infants undergoing TH often require treatment for pain and agitation which may lead to further brain injury. For instance, morphine use in animal models has been shown to induce neuronal apoptosis. Dexmedetomidine is a potent \u03b1<jats:sub>2<\/jats:sub>-adrenergic receptor agonist that may be a better alternative to morphine for newborns with HIE treated with TH. Dexmedetomidine provides sedation, analgesia, and prevents shivering but does not suppress ventilation. Importantly, there is increasing evidence that dexmedetomidine has neuroprotective properties. Even though there are limited data on pharmacokinetics (PK), safety and efficacy of dexmedetomidine in infants with HIE, it has been increasingly administered in many centers.<\/jats:p><jats:p><jats:bold>Objectives:<\/jats:bold> To review the current approach to treatment of pain, sedation and shivering in infants with HIE undergoing TH, and to describe a new phase II safety and pharmacokinetics randomized controlled trial that proposes the use of dexmedetomidine vs. morphine in this population.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> This article presents an overview of the current management of pain and sedation in critically ill infants diagnosed with HIE and undergoing TH for 72 h. The article describes the design and methodology of a randomized, controlled, unmasked multicenter trial of dexmedetomidine vs. morphine administration enrolling 50 (25 per arm) neonates \u226536 weeks of gestation with moderate or severe HIE undergoing TH and that require pain\/sedation treatment.<\/jats:p><jats:p><jats:bold>Results and Conclusions:<\/jats:bold> Dexmedetomidine may be a better alternative to morphine for the treatment of pain and sedation in newborns with HIE treated with TH. There is increasing evidence that dexmedetomidine has neuroprotective properties in several preclinical studies of injury models including ischemia-reperfusion, inflammation, and traumatic brain injury as well as adult clinical trials of brain trauma. The Dexmedetomidine Use in Infants undergoing Cooling due to Neonatal Encephalopathy (DICE) trial will evaluate whether administration of dexmedetomidine vs. morphine is safe, establish dexmedetomidine optimal dosing by collecting opportunistic PK data, and obtain preliminary neurodevelopmental data to inform a large Phase III efficacy trial with long term neurodevelopment impairment as the primary outcome.<\/jats:p>","DOI":"10.3389\/fpain.2021.770511","type":"journal-article","created":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T11:00:25Z","timestamp":1638874825000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":24,"title":["Dexmedetomidine Use in Infants Undergoing Cooling Due to Neonatal Encephalopathy (DICE Trial): A Randomized Controlled Trial: Background, Aims and Study Protocol"],"prefix":"10.3389","volume":"2","author":[{"given":"Mariana","family":"Baserga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara L.","family":"DuPont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betsy","family":"Ostrander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Minton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Sheffield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred H.","family":"Balch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy M.","family":"Bahr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin M.","family":"Watt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,12,7]]},"reference":[{"key":"B1","first-page":"1969","article-title":"Global, regional, and national causes of child mortality in 2008: a systematic analysis","volume-title":"Lancet.","author":"Black","year":"2010"},{"key":"B2","first-page":"329","article-title":"Epidemiology of neonatal encephalopathy and hypoxic-ischaemic encephalopathy","volume-title":"Early Hum Dev.","author":"Kurinczuk","year":"2010"},{"key":"B3","first-page":"593","article-title":"Global burden, epidemiologic trends, and prevention of intrapartum-related deaths in low-resource settings","volume-title":"Clin Perinatol.","author":"Ariff","year":"2016"},{"key":"B4","first-page":"1574","article-title":"Whole-body hypothermia for neonates with hypoxic-ischemic encephalopathy","volume-title":"N Engl J Med.","author":"Shankaran","year":"2005"},{"key":"B5","first-page":"1349","article-title":"Moderate hypothermia to treat perinatal asphyxial encephalopathy","volume-title":"N Engl J Med.","author":"Azzopardi","year":"2009"},{"key":"B6","doi-asserted-by":"publisher","first-page":"c363","DOI":"10.1136\/bmj.c363","article-title":"Neurological outcomes at 18 months of age after moderate hypothermia for perinatal hypoxic ischaemic encephalopathy: synthesis and meta-analysis of trial data","volume":"340","author":"Edwards","year":"2010","journal-title":"BMJ"},{"key":"B7","first-page":"57","article-title":"Effect of depth and duration of cooling on death or disability at age 18 months among neonates with hypoxic-ischemic encephalopathy: a randomized clinical trial","volume-title":"JAMA.","author":"Shankaran","year":"2017"},{"key":"B8","first-page":"1060","article-title":"Association between sedation-analgesia and neurodevelopment outcomes in neonatal hypoxic-ischemic encephalopathy","volume-title":"J Perinatol.","author":"Natarajan","year":"2018"},{"key":"B9","first-page":"1008","article-title":"Differences in patient characteristics and care practices between two trials of therapeutic hypothermia","volume-title":"Pediatr Res.","author":"Bonifacio","year":"2019"},{"key":"B10","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci4020321","article-title":"The neurodevelopmental impact of neonatal morphine administration","volume-title":"Brain Sci.","author":"Attarian","year":"2014"},{"key":"B11","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2796.2005.01569.x","article-title":"Opioids and opiates: analgesia with cardiovascular, haemodynamic and immune implications in critical illness","volume-title":"J Intern Med.","author":"Molina","year":"2006"},{"key":"B12","doi-asserted-by":"crossref","DOI":"10.1016\/j.siny.2014.10.003","article-title":"Analgesics, sedatives, anticonvulsant drugs, and the cooled brain","volume-title":"Semin Fetal Neonatal Med.","author":"Wassink","year":"2015"},{"key":"B13","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3389\/fped.2020.00030","article-title":"Early neonatal pain-a review of clinical and experimental implications on painful conditions later in life","volume":"8","author":"Williams","year":"2020","journal-title":"Front Pediatr."},{"key":"B14","doi-asserted-by":"crossref","DOI":"10.1203\/00006450-200109000-00017","article-title":"Twenty-four hours of mild hypothermia in unsedated newborn pigs starting after a severe global hypoxic-ischemic insult is not neuroprotective","volume-title":"Pediatr Res.","author":"Thoresen","year":"2001"},{"key":"B15","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41372-019-0533-4","article-title":"Opioid and benzodiazepine use during therapeutic hypothermia in encephalopathic neonates","volume":"40","author":"Berube","year":"2020","journal-title":"J Perinatol."},{"key":"B16","article-title":"Morphine induces apoptosis of human microglia and neurons","volume-title":"Neuropharmacology.","author":"Hu","year":"2002"},{"key":"B17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijdevneu.2013.02.009","article-title":"Morphine-enhanced apoptosis in selective brain regions of neonatal rats","volume-title":"Int J Dev Neurosci.","author":"Bajic","year":"2013"},{"key":"B18","doi-asserted-by":"crossref","DOI":"10.1203\/PDR.0b013e31820bd165","article-title":"Effects of neonatal stress and morphine on murine hippocampal gene expression","volume-title":"Pediatr Res.","author":"Juul","year":"2011"},{"key":"B19","article-title":"Modulation of brain development by morphine: effects on central motor systems and behavior","volume-title":"Peptides.","author":"Handelmann","year":"1985"},{"key":"B20","first-page":"1673","article-title":"Effects of morphine analgesia in ventilated preterm neonates: primary outcomes from the NEOPAIN randomised trial","volume-title":"Lancet.","author":"Anand","year":"2004"},{"key":"B21","first-page":"2419","article-title":"Routine morphine infusion in preterm newborns who received ventilatory support: a randomized controlled trial","volume-title":"JAMA.","author":"Simons","year":"2003"},{"key":"B22","doi-asserted-by":"publisher","first-page":"CD011107","DOI":"10.1002\/14651858.CD011107.pub2","article-title":"Alpha-2 adrenergic agonists for the prevention of shivering following general anaesthesia","volume":"10","author":"Lewis","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"B23","first-page":"1069","article-title":"Hemodynamic effects of dexmedetomidine in critically ill neonates and infants with heart disease","volume-title":"Pediatr Cardiol.","author":"Lam","year":"2012"},{"key":"B24","doi-asserted-by":"publisher","first-page":"918361","DOI":"10.1155\/2015\/918361","article-title":"Dexmedetomidine ameliorate CLP-induced rat intestinal injury via inhibition of inflammation","volume":"2015","author":"Chen","year":"2015","journal-title":"Mediators Inflamm."},{"key":"B25","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1471-2377-12-20","article-title":"Dexmedetomidine is neuroprotective in an in vitro model for traumatic brain injury","volume":"12","author":"Schoeler","year":"2012","journal-title":"BMC Neurol."},{"key":"B26","doi-asserted-by":"crossref","DOI":"10.1111\/j.1399-6576.2009.02177.x","article-title":"Dexmedetomidine provides cortical neuroprotection: impact on anaesthetic-induced neuroapoptosis in the rat developing brain","volume-title":"Acta Anaesthesiol Scand.","author":"Sanders","year":"2010"},{"key":"B27","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijsu.2012.12.003","article-title":"The protective effects of dexmedetomidine on the liver and remote organs against hepatic ischemia reperfusion injury in rats","volume-title":"Int J Surg.","author":"Tufek","year":"2013"},{"key":"B28","doi-asserted-by":"crossref","DOI":"10.1093\/bja\/aex222","article-title":"Dexmedetomidine-mediated neuroprotection against sevoflurane-induced neurotoxicity extends to several brain regions in neonatal rats","volume-title":"Br J Anaesth.","author":"Perez-Zoghbi","year":"2017"},{"key":"B29","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2018.05.040","article-title":"Dexmedetomidine attenuated early brain injury in rats with subarachnoid haemorrhage by suppressing the inflammatory response: the TLR4\/NF-kappaB pathway and the NLRP3 inflammasome may be involved in the mechanism","volume-title":"Brain Res.","author":"Yin","year":"2018"},{"key":"B30","article-title":"Dexmedetomidine attenuates traumatic brain injury: action pathway and mechanisms","volume-title":"Neural Regen Res.","author":"Wang","year":"2018"},{"key":"B31","doi-asserted-by":"crossref","DOI":"10.1177\/0300060517698330","article-title":"Effect and placental transfer of dexmedetomidine during caesarean section under epidural anaesthesia","volume-title":"J Int Med Res.","author":"Wang","year":"2017"},{"key":"B32","doi-asserted-by":"publisher","first-page":"6643171","DOI":"10.1155\/2021\/6643171","article-title":"Dexmedetomidine alleviates hypoxia-induced synaptic loss and cognitive impairment via inhibition of microglial NOX2 activation in the hippocampus of neonatal rats","volume":"2021","author":"Chen","year":"2021","journal-title":"Oxid Med Cell Longev."},{"key":"B33","article-title":"Effects of alpha(2)-adrenoceptor agonists on perinatal excitotoxic brain injury: comparison of clonidine and dexmedetomidine","volume-title":"Anesthesiology.","author":"Laudenbach","year":"2002"},{"key":"B34","doi-asserted-by":"crossref","first-page":"87armacolbtype","DOI":"10.1016\/j.ejphar.2004.08.044","article-title":"Dexmedetomidine produces its neuroprotective effect via the alpha 2A-adrenoceptor subtype","volume":"502","author":"Ma","year":"2004","journal-title":"Eur J Pharmacol."},{"key":"B35","doi-asserted-by":"crossref","first-page":"25Anesths","DOI":"10.1016\/j.jclinane.2017.04.003","article-title":"The protective effects of dexmedetomidine on ischemic brain injury: A meta-analysis","volume":"40","author":"Jiang","year":"2017","journal-title":"J Clin Anesth."},{"key":"B36","doi-asserted-by":"crossref","DOI":"10.1111\/aas.12318","article-title":"Pharmacokinetics of dexmedetomidine combined with therapeutic hypothermia in a piglet asphyxia model","volume-title":"Acta Anaesthesiol Scand.","author":"Ezzati","year":"2014"},{"key":"B37","doi-asserted-by":"publisher","first-page":"2582965","DOI":"10.1155\/2020\/2582965","article-title":"Dexmedetomidine pharmacokinetics in neonates with hypoxic-ischemic encephalopathy receiving hypothermia","volume":"2020","author":"McAdams","year":"2020","journal-title":"Anesthesiol Res Pract."},{"key":"B38","first-page":"276","article-title":"A phase II\/III, multicenter, safety, efficacy, and pharmacokinetic study of dexmedetomidine in preterm and term neonates","volume-title":"J Pediatr","author":"Chrysostomou","year":"2014"},{"key":"B39","article-title":"Central hypotensive effects of the alpha2a-adrenergic receptor subtype","volume-title":"Science.","author":"MacMillan","year":"1996"},{"key":"B40","article-title":"The effects of increasing plasma concentrations of dexmedetomidine in humans","volume-title":"Anesthesiology.","author":"Ebert","year":"2000"},{"key":"B41","doi-asserted-by":"publisher","first-page":"112","DOI":"10.5863\/1551-6776-20.2.112","article-title":"Characterization of dexmedetomidine dosing and safety in neonates and infants","volume":"20","author":"Estkowski","year":"2015","journal-title":"J Pediatr Pharmacol Ther."},{"key":"B42","article-title":"Dexmedetomidine does not alter the sweating threshold, but comparably and linearly decreases the vasoconstriction and shivering thresholds","volume-title":"Anesthesiology.","author":"Talke","year":"1997"},{"key":"B43","doi-asserted-by":"crossref","DOI":"10.1016\/j.jclinane.2006.08.011","article-title":"Hypothermia-induced bradycardia in a neonate receiving dexmedetomidine","volume-title":"J Clin Anesth.","author":"Finkel","year":"2007"},{"key":"B44","doi-asserted-by":"publisher","first-page":"e168873","DOI":"10.1055\/s-0038-1669938","article-title":"Dexmedetomidine for sedation of neonates with HIE undergoing therapeutic hypothermia: a single-center experience","volume":"8","author":"O'Mara","year":"2018","journal-title":"AJP Rep."},{"key":"B45","article-title":"Is dexmedetomidine a potential neuroprotective agent for term neonates with hypoxic-ischemic encephalopathy?","volume-title":"Pediatric Anesth Crit Care J.","author":"Surkov","year":"2019"},{"key":"B46","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1038\/s41372-021-00998-8","article-title":"Dexmedetomidine vs. intermittent morphine for sedation of neonates with encephalopathy undergoing therapeutic hypothermia","volume":"41","author":"Cosnahan","year":"2021","journal-title":"J Perinatol."},{"key":"B47","doi-asserted-by":"crossref","DOI":"10.1177\/0885066608324389","article-title":"Bradycardia during dexmedetomidine and therapeutic hypothermia","volume-title":"J Intensive Care Med.","author":"Tobias","year":"2008"},{"key":"B48","doi-asserted-by":"crossref","DOI":"10.1089\/ther.2016.0003","article-title":"Effect of hypothermia and targeted temperature management on drug disposition and response following cardiac arrest: a comprehensive review of preclinical and clinical investigations","volume-title":"Ther Hypothermia Temp Manag.","author":"Anderson","year":"2016"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1056\/NEJMra035092","article-title":"Developmental pharmacology\u2014drug disposition, action, and therapy in infants and children","volume":"349","author":"Kearns","year":"2003","journal-title":"N Engl J Med."},{"key":"B50","doi-asserted-by":"crossref","DOI":"10.1038\/sj.jp.7211861","article-title":"Clinical reliability and validity of the N-PASS: neonatal pain, agitation and sedation scale with prolonged pain","volume-title":"J Perinatol.","author":"Hummel","year":"2008"},{"key":"B51","first-page":"3242","article-title":"Metabolic impact of shivering during therapeutic temperature modulation: the Bedside Shivering Assessment Scale","volume-title":"Stroke.","author":"Badjatia","year":"2008"},{"key":"B52","doi-asserted-by":"publisher","first-page":"104828","DOI":"10.1016\/j.earlhumdev.2019.104828","article-title":"Therapeutic hypothermia and N-PASS; results from implementation in a level 3 NICU","volume":"137","author":"Uner","year":"2019","journal-title":"Early Hum Dev."},{"key":"B53","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2017.08.048","article-title":"Characteristics and changes of pediatric therapeutic trials under the best pharmaceuticals for children act","volume-title":"J Pediatr.","author":"Avant","year":"2018"},{"key":"B54","doi-asserted-by":"crossref","DOI":"10.2174\/1574884709666140520153308","article-title":"Pharmacokinetic studies in infants using minimal-risk study designs","volume-title":"Curr Clin Pharmacol.","author":"Autmizguine","year":"2014"},{"key":"B55","doi-asserted-by":"crossref","DOI":"10.1007\/s10928-018-9576-y","article-title":"A pharmacokinetic model for amiodarone in infants developed from an opportunistic sampling trial and published literature data","volume-title":"J Pharmacokinet Pharmacodyn.","author":"Dallefeld","year":"2018"},{"key":"B56","doi-asserted-by":"crossref","DOI":"10.1038\/clpt.2014.134","article-title":"Use of opportunistic clinical data and a population pharmacokinetic model to support dosing of clindamycin for premature infants to adolescents","volume-title":"Clin Pharmacol Ther.","author":"Gonzalez","year":"2014"},{"key":"B57","article-title":"Physiologically based pharmacokinetic modeling in regulatory science: an update from the U.S Food and Drug Administration in regulatory scienceneh Iupport","volume-title":"J Pharm Sci.","author":"Grimstein","year":"2019"},{"key":"B58","first-page":"1343","article-title":"Development of a pediatric physiologically-based pharmacokinetic model of clindamycin using opportunistic pharmacokinetic data","volume-title":"Clin Pharmacokinet.","author":"Hornik","year":"2017"},{"key":"B59","doi-asserted-by":"crossref","DOI":"10.1038\/jp.2016.79","article-title":"An opportunistic study evaluating pharmacokinetics of sildenafil for the treatment of pulmonary hypertension in infants","volume-title":"J Perinatol.","author":"Thakkar","year":"2016"},{"key":"B60","first-page":"3013","article-title":"Characterization of the population pharmacokinetics of ampicillin in neonates using an opportunistic study design","volume-title":"Antimicrob Agents Chemother.","author":"Tremoulet","year":"2014"},{"key":"B61","doi-asserted-by":"publisher","first-page":"e4487","DOI":"10.1002\/bmc.4487","article-title":"An improved ultra-high-performance liquid chromatography-tandem mass spectrometric method for the quantitation of dexmedetomidine in small volume of pediatric plasma","volume":"33","author":"Moorthy","year":"2019","journal-title":"Biomed Chromatogr."},{"key":"B62","doi-asserted-by":"crossref","DOI":"10.1067\/mpd.2001.111325","article-title":"Neurologic examination in infants with hypoxic-ischemic encephalopathy at age 9 to 14 months: use of optimality scores and correlation with magnetic resonance imaging findings","volume-title":"J Pediatr.","author":"Haataja","year":"2001"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.3390\/jcm8081247","article-title":"Early neurological assessment in infants with hypoxic ischemic encephalopathy treated with therapeutic hypothermia","volume":"8","author":"Romeo","year":"2019","journal-title":"J Clin Med"},{"key":"B64","doi-asserted-by":"crossref","DOI":"10.1001\/jamapediatrics.2017.1689","article-title":"Early, accurate diagnosis and early intervention in cerebral palsy: advances in diagnosis and treatment","volume-title":"JAMA Pediatr.","author":"Novak","year":"2017"},{"key":"B65","doi-asserted-by":"publisher","first-page":"e20193449","DOI":"10.1542\/peds.2019-3449","article-title":"Promoting optimal development: identifying infants and young children with developmental disorders through developmental surveillance and screening","volume":"145","author":"Lipkin","year":"2020","journal-title":"Pediatrics"},{"key":"B66","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1907423","article-title":"A randomized trial of erythropoietin for neuroprotection in preterm infants","volume-title":"N Engl J Med.","author":"Juul","year":"2020"},{"key":"B67","doi-asserted-by":"crossref","DOI":"10.1038\/pr.2015.101","article-title":"Darbepoetin administration to neonates undergoing cooling for encephalopathy: a safety and pharmacokinetic trial","volume-title":"Pediatr Res.","author":"Baserga","year":"2015"},{"key":"B68","doi-asserted-by":"crossref","DOI":"10.1136\/archdischild-2013-304037","article-title":"Blinding in pharmacological trials: the devil is in the details","volume-title":"Arch Dis Child.","author":"Wan","year":"2013"},{"key":"B69","doi-asserted-by":"publisher","first-page":"CD003311","DOI":"10.1002\/14651858.CD003311.pub3","article-title":"Cooling for newborns with hypoxic ischaemic encephalopathy","volume":"2013","author":"Jacobs","year":"2013","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Frontiers in Pain Research"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpain.2021.770511\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T11:01:20Z","timestamp":1638874880000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpain.2021.770511\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,7]]},"references-count":69,"alternative-id":["10.3389\/fpain.2021.770511"],"URL":"https:\/\/doi.org\/10.3389\/fpain.2021.770511","relation":{},"ISSN":["2673-561X"],"issn-type":[{"value":"2673-561X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,7]]},"article-number":"770511"}}